Brightonix Imaging’s High-Performance ‘PHAROS’ PET Receives FDA Clearance
- Post by
- Admin
- Date
- 2025-08-27
Brightonix Imaging’s High-Performance ‘PHAROS’ PET Receives FDA Clearance
Brightonix, South Korea – August 15, 2025 –
Brightonix Imaging, a global leader in cutting-edge medical imaging technology,
is proud to announce that its flagship product, the PHAROS PET Scanner,
has received FDA clearance for commercial distribution in the United
States. This milestone marks a new era of precision and efficiency in nuclear
imaging and positions Brightonix Imaging at the forefront of medical
innovation.
The PHAROS PET is a
state-of-the art clinical positron emission tomography (PET) system designed to
deliver exceptional image quality, offering healthcare
providers a powerful tool for early disease detection, precise diagnosis, and
optimized treatment planning. With its innovative design and
enhanced performance capabilities, the PHAROS scanner is poised to set new
standards in neurology. Furthermore, the
PHAROS is multi-functional with the ability to physically orient the patient
seat and detector configurations for extremity and breast imaging, as well as
converting to both lying and
seated modes for brain imaging.
